Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivaroxaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivaroxaban SCHEMBL3914 | 1.00 | F10 (1.00) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL7721848 | 1.00 | F10 (1.00) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL14796329 | 0.99 | F10 (0.98) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL14796410 | 0.95 | F10 (0.90) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL30893049 | 0.94 | F10 (0.90) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL3375861 | 0.93 | F10 (0.86) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL13068882 | 0.92 | F10 (0.85) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL5478295 | 0.92 | F10 (0.85) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL12396723 | 0.91 | F10 (0.83) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL20802158 | 0.91 | F10 (0.83) | F10F2ABCB11ST14CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3003277-B1 | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION COMPRISING RIVAROXABAN | SANDOZ AG (CH) | 2019-02-20 | — | — | EP | claimed |
| US-20160120870-A1 | THE PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION COMPRISING RIVAROXABAN | SANDOZ AG (CH) | 2016-05-05 | — | — | US | claimed |
| EP-3003277-A1 | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION COMPRISING RIVAROXABAN | Sandoz AG (CH) | 2016-04-13 | — | — | EP | claimed |
| WO-2014191446-A1 | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION COMPRISING RIVAROXABAN | SANDOZ AG (CH) | 2014-12-04 | — | — | WO | claimed |
| EP-2808011-A1 | Process for the preparation of a pharmaceutical composition comprising Rivaroxaban | SANDOZ AG (CH) | 2014-12-03 | — | — | EP | claimed |
| EP-1845961-A1 | PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS | Bayer HealthCare AG (DE) | 2007-10-24 | — | — | EP | claimed |
| WO-2006079474-A1 | PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS | BAYER HEALTHCARE AG (DE) | 2006-08-03 | — | — | WO | claimed |
| EP-1685841-A1 | Prevention and treatment of thromboembolic disorders | Bayer Health Care Aktiengesellschaft (DE) | 2006-08-02 | — | — | EP | claimed |
| EP-4597115-A2 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK | Takeda Pharmaceutical Company Limited (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-4574040-A2 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | Takeda Pharmaceutical Company Limited (JP) | 2025-06-25 | — | — | EP | disclosed |
| US-20250186758-A1 | CIRCULATORY SUPPORT DEVICE WITH DRUG ELUTING COATING | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250172567-A1 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-05-29 | — | — | US | disclosed |
| EP-4552633-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AMORPHOUS SOLID SOLUTIONS OF RIVAROXABAN AND COPOVIDONE AND PREPARATION METHODS THEREOF | Zentiva K.S. (CZ) | 2025-05-14 | — | — | EP | disclosed |
| EP-3909509-B1 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | TAKEDA PHARMACEUTICALS CO (JP) | 2025-04-09 | — | — | EP | disclosed |
| EP-1526132-A2 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | Bayer HealthCare AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| EP-1261606-B1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1411932-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003000256-A9 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER AG (DE) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003000256-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | SERPINC1, XDH, SDHB | F10 41/4885F2 4/4885ABCB11 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.